Introduction
The European Society of Human Reproduction and Embryology (ESHRE) Preimplantation Genetic Diagnosis (PGD) Consortium was established in 1997. Since 1999, eight data collections of PGD for autosomal and sex-linked monogenic diseases and chromosome abnormalities, preimplantation genetic screening (PGS) and social sex selection have been published (ESHRE PGD Consortium Steering Committee, 1999 , 2000 Sermon et al., 2005 Sermon et al., , 2007 Harper et al., 2006 Harper et al., , 2008b Goossens et al., 2008) . This report summarizes data IX collected for the calendar year 2006 and the subsequent pregnancies. As it was reported for the first time in data VIII, data IX also includes the delivery rate for each indication as well as a graph of the pregnancy rates for each centre (Fig. 1 ).
Materials and Methods
Data were collected using a FileMaker Pro 5, 6 or 8 database, consisting of files for cycle, pregnancy and baby records. The submitted data were thoroughly analysed to identify omissions and any ambivalent data. Corrections were requested from the participating centres. Records with insufficient data, e.g. with no cycle or patient identification or no clear indication or from the wrong time period were excluded from the calculations. In-depth corrections and tables were made by expert co-authors. Clinical pregnancies were defined as the presence of one or more fetal hearts at 6 weeks gestation. Implantation rate was defined as the number of fetal hearts per 100 embryos transferred. Delivery rate was defined as the percentage of pregnancies with delivery per oocyte retrieval (OR) and per embryo transfer procedure.
Results
The number of centres that become members of the PGD Consortium increases annually. Data from 57 centres were included in this report. The results are represented in tables according to an established layout. Accompanying text is deliberately concise and seven tables are available in an electronic version only: Supplementary An overview of all cycles collected previously in data collections I -VIII is shown in Table Ia , whereas an overview of the current data collection is shown in Table Ib. For all indications for PGD/PGS, intra cytoplasmic sperm injection (ICSI) was the most often used method of fertilization, and cleavage stage aspiration was the most commonly used method of biopsy. Overall zona pellucida drilling was more commonly performed using a laser. The mechanical method was used more often for social sexing since the centre that reported the largest proportion of the cycles for social sexing often uses this method. Tables IIa and IIb summarize the 2712 and 812 cycles to OR collected for data collections I -VIII and IX, respectively. As for previous years, data IX showed that PGD for reciprocal translocations was performed more often than for Robertsonian translocations or other types of chromosome abnormalities. For data IX, 11 411 oocytes were collected, 72% (7056/9794) fertilized, 72% (5062/7056) embryos were biopsied and 99% (5015/5062) embryos were successfully biopsied. Of the embryos successfully biopsied, 94% (4725/5015) gave a diagnostic result, of which only 24% (1126/4725) were transferable. From 812 OR procedures, only 61% (493/812) resulted in an embryo transfer procedure. This is in agreement with previous data showing that a high level of chromosomally abnormal embryos is found in these patients. A positive hCG was obtained in 174 cycles, with a positive heart beat in 141 cycles [17% per OR (141/812) and 29% per embryo transfer (141/493)]. This gave an implantation rate of 22% (178/821). Finally, the delivery rate was 15% per OR (126/812) and 26% per embryo transfer (126/493). There were 14/140 miscarriages (10% per clinical pregnancy) and 1/141 pregnancy was lost to follow-up. Tables IIIa and IIIb summarize the 924 and 133 cycles to OR collected for data collections I -VIII and IX, respectively. This year, again, fluorescence in situ hybridization (FISH) was the only method used for sexing cycles. For data IX, 1747 oocytes were collected, 72% (1141/1574) fertilized, 75% (851/1141) embryos were biopsied and 99% (844/851) was successfully biopsied. Of the embryos successfully biopsied, 95% (800/844) gave a diagnostic result, of which only 34% (275/800) were transferable (female). From 133 OR procedures, only 74% (98/133) resulted in an embryo transfer procedure. A positive hCG was obtained in 32 cycles, with a positive heart beat in 25 cycles [19% per OR (25/133) and 26% per embryo transfer (25/98)]. This gave an implantation rate of 19% (32/163). These pregnancy rates were slightly lower than in the previous data collections. Finally, the delivery rate was 18% per OR (24/133) and 24% per embryo transfer (24/98). There was 1/25 miscarriage (4% per clinical pregnancy) and no clinical pregnancies lost to follow-up. For data IX, 12 402 oocytes were collected and 75% (7622/10 135) fertilized. ICSI was used in 926 cycles (of which 9 were subsequently frozen) and in vitro fertilization (IVF) in the 5 cycles that were analysed using FISH. For the first time since data collection was initiated, all cycles that were analysed by polymerase chain reaction (PCR) used ICSI for embryo fertilization, as recommended by our best-practice guidelines (Thornhill et al., 2005) . A total of 70% (5342/7622) of the embryos were biopsied and 99% (5306/5342) were successfully biopsied. Of the embryos successfully biopsied, 89% (4726/5306) gave a diagnostic result, of which 45% (2374/5306) were transferable. From 931 OR procedures, 78% (724/931) resulted in an embryo transfer procedure. A positive hCG was obtained in 291 cycles, with a positive heart beat in 237 cycles [26% per OR (237/931) and 33% per embryo transfer (237/724)] and 300 fetal hearts, giving an overall implantation rate of 23% (300/1336). These pregnancy rates were notably higher than in the previous data collections. Finally, the delivery rate was 23% per OR (212/931) and 29% per embryo transfer (212/724). There were 23/237 miscarriages (10% per clinical pregnancy) and 2/237 clinical pregnancies lost to follow-up.
PGD cycles for chromosomal abnormalities

PGD cycles for sexing for X-linked diseases
Overall, the number of PGD cycles performed for monogenic disorders between January and December 2006 was almost double that of the previous year (data collection VIII), representing a marked increase. However, there were no marked changes with respect to the progress and outcome of cycles, including the embryology, rates of diagnosis and clinical outcome, such as clinical pregnancy and embryo implantation rates (Harper et al., 2008a) . Tables Va and Vb From 3900 cycles, 368 involved the biopsy of only one embryo and 474 involved the biopsy of two embryos. As stated in data VII (Harper et al., 2008a, b) , in the majority of cases these embryos should be replaced without biopsy.
Preimplantation genetic screening
For the first time in the data collection, 3 cycles were performed using a PCR-based micro-array, in all other 3784 cycles FISH was used.
The column 'others' contains various indications, such as mosaic embryos and single or double embryo transfer, as well as cycles with multiple indications.
The ESHRE PGS Task Force continues in an attempt to set up a multicentre randomized controlled study for PGS. The discussion about the efficacy of PGS is still very much alive and asks for clear answers.
PGD cycles for social sexing Table VIa and VIb summarize the 497 and 82 cycles to OR collected for data collections I -VIII and IX, respectively. For data IX, 1150 oocytes were collected, 73% (721/988) fertilized, 79% (568/721) embryos were biopsied and 99% (565/568) was successfully biopsied. Of the embryos successfully biopsied 87% (494/565) gave a diagnostic result, of which only 42% (209/494) were transferable (of the desired sex). From 82 OR procedures, only 79% (65/82) resulted in an embryo transfer procedure. A positive hCG was obtained in 20 cycles, with a positive heart beat in 13 cycles [16% per OR (13/82) and 20% per embryo transfer (13/65)]. This gave an implantation rate of 11% (13/119). These pregnancy rates were similar to the previous data collections. Finally, the delivery rate was 15% per OR (12/ 82) and 18% per embryo transfer (12/65). There was 1/13 miscarriage (8% per clinical pregnancy) and no clinical pregnancies lost to follow-up.
More than 50% of the cycles were for couples who requested a male embryo (47 cycles) rather than a female embryo (35 cycles). This number is slightly lower than in the last data collection (Goossens et al., 2008) . There are more males requested than females as a large number of cases are done in the USA where MicroSort w sperm separation is used and is more efficient at selecting X bearing sperm. Two cycles were on frozen -thawed embryos only so they were not counted as cycles with an OR, but were counted as cycles going to PGD. Includes two cycles done also with FISH for a Roberstonian translocation.
Pregnancies and babies
2
Includes two cycles done also with FISH, one for diabetes insipidus (sexing) and the other for PGS.
3
Includes five cycles done also for retinitis pigmentosa and one with FISH for PGS (advanced maternal age: AMA).
4
Includes one cycle also for DMD.
5
Includes three cycles using FISH for a microdeletion. This report again confirms that pregnancies and babies born after PGD are very similar to the pregnancies obtained and babies born after ICSI treatment (Bonduelle et al., 2002) . In our series, the number of multiple pregnancies remains high (296/1292, 23%) . This means 37% (446/1206) of the babies born are part of a multiplet at birth.
Misdiagnoses
Tables XIIIa and XIIIb summarize the misdiagnoses reported for data collections I -VIII and IX, respectively. For data IX, four misdiagnoses have been reported, all after FISH for PGS. The Consortium has published a paper on the possible causes of misdiagnosis in PGD (Wilton et al., 2009 ). Figure 1 shows the pregnancy rate for each centre for data IX. The pregnancy rate ranges from 0 to 50% with the average being 21%. Although it could be expected that centres carrying out lower numbers of cycles may have lower rates owing to less experience, the findings indicate that some of the most active centres fall below the average 21% pregnancy rate and even have pregnancy rates lower than some of the centres performing few cycles.
Success of individual centres
Discussion
This ninth report of the ESHRE PGD Consortium demonstrates, as in previous years, the continuing increase in the number of PGD cycles, with subsequent pregnancies and babies. It must be stated that for these data collection, a large number of PGS cycles from previous years were included. They were part of an ongoing study and could not be reported before. It should be emphasized that the follow-up of pregnancies resulting from PGD cycles, and preferably also babies born, is, as part of good practice, essential to complete. It gives information on the evaluation of the overall procedure and is strongly recommended for all centres involved in PGD. Data collection IX show that more and more centres do their very best to retrieve these data.
The number of centres participating in the data collection of 2006 was much higher compared with 2005 (57 versus 39). We welcomed many new members during the last 2 years. There are still two levels of membership of the Consortium; full membership for centres that submit annual data and associate membership for centres that cannot submit data (including new clinics, IVF units that work with a diagnostic lab that is a member of the Consortium). Associate centres performing PGD must send the summary data.
As always the centres which submit data have access to the raw data, whereas the associate centres will be allowed to participate in the annual Consortium meetings and they are sent the quarterly Consortium newsletter.
Since ESHRE have set up a PGS task force, the work of the PGS working group is complete.
There are four active Consortium working groups and their work is ongoing. The database group is working on simplifying the results of pregnancies and babies as these data are difficult to summarize. A new database is in preparation for the outcome of the transfer of biopsied/thawed embryos. This will only consider embryos that were frozen after biopsy and PGD. The misdiagnosis working group has published a paper on misdiagnosis (Wilton et al., 2009) and is setting up a study of the analysis of untransferred embryos. The accreditation working group ran a workshop on the Quality Management and Accreditation process in PGD clinics and laboratories in Eleven cycles with embryos frozen without biopsy or failed diagnosis included.
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Three embryos frozen without biopsy were not included.
2008 and will run this again in London in 2010. They are preparing a guide to PGD laboratory accreditation. Working towards accreditation is one of the most important issues being discussed by the PGD Consortium. This has been aided by our external quality assurance (EQA) schemes for FISH and PCR. The pilot for the FISH was run in 2008 and was an online scheme plus the submission of a retrospective case. The 2009 FISH EQA will involve the online workup and assessment of two PGD cases. The PCR EQA will involve sending PGD Centres DNA and single cells for analysis, and the pilot will be run in 2009. Good quality management will help centres become more efficient. A new working group on Guideline development and update has been formed. ESHRE has recently developed a set of Guidelines on writing Guidelines which will, of course, be followed to make guideline documents on PGD in the most appropriate way. TOP, termination of pregnancy. Two TOPs for ancephalocoele, one TOP for social reasons, one TOP of twin with misdiagnosis for CMT disease 1a.
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One heterotrophic gestation continued as singleton after reduction of extrauterine gestation at 6 weeks.
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One triplet: fetal reduction, followed by amniocentesis and loss of remaining twin at 16 weeks (one fetal sac counted in reduction, two in miscarriage, one second trimester pregnancy loss after miscarriage counted).
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TOP after misdiagnosis (five): One misdiagnosis for sexing, FISH, female fetus, indication social sexing; one misdiagnosis for b-Thal, PCR; one misdiagnosis for myotonic dystrophy, PCR, one misdiagnosis after PGS, karyotype 45,X; one misdiagnosis for a reciprocal translocation 46,XY,der(15)t(3;15)(q25.1;q26.3). TOP after ultrasound (four): enlarged lateral ventricle, two singletons with cardiopathy, one singleton with tetralogy of Fallot. TOP after amniocentesis, not related to the PGD: trisomy 18, indication for PGD parent carrier of reciprocal translocation not involving chromosome 18; one polymalformation; one cystic hygroma, failed karyotype; one Turner mosaic, one spina bifida. 8 One misdiagnosis for sexing, PCR, indication Duchenne, twin pregnancy, selective termination of male fetus. Cycle done in 1996, Y-specific amplification only.
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One misdiagnosis (47,XXX after PGS for RIF) lost to FU. of the manuscript.
Many thanks also to all of the centres who participated in data collection IX. 
